*Corresponding Author: Calixto Machado, Institute of Neurology and Neurosurgery, 29 y D, Vedado La Havana, Cuba.
Citation: Calixto Machado, Alina Gonzalez-Quevedo, Yanín Machado, Mauricio Chinchilla, Jonathan Fellus, Arthur Schift, Beata Drobná Sániová and Michal Drobný (2022) Early Prevention of Hypoxemia in COVID-19 Patients can avert the Cytokine Storm. Clinical Medical Reviews and Reports. 4(4); DOI: 10.31579/2690-8794/118
Copyright: © 2022 Calixto Machado, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 03 December 2021 | Accepted: 13 January 2022 | Published: 01 February 2022
Keywords: covid-19; sars-cov-2; cytokine storm; acute respiratory distress syndrome (ards); non-invasive ventilation; cpap
Abstract
Background: In COVID-19, an exaggerated pro-inflammatory response, known as cytokine storm (CS). The anti-inflammatory system's CS–mediated response is an ineffective immunological control, leading to tissue damage, multiorgan failure, acute respiratory distress syndrome, and death.
Objectives: To review and discuss the tie relationship between hypoxemia and the CS, proposing an early avoidance of periods of hypoxemia to avert the CS.
Methods: We review the literature on this topic providing a pathophysiological background to support our proposal of avoiding periods of hypoxemia in the early stages of the disease.
Results: Cytokine-mediated lung endothelial and epithelial cell injury may damage the integrity of the blood–air barrier, promoting vascular permeability, alveolar edema, infiltration, and the presence of inflammatory cells, starving the blood of oxygen, causing hypoxemia. Hypoxemia triggers factors like HIF-1α, which regulates essential cellular processes, including cell proliferation, metabolism, and angiogenesis. HIF-1α is activated during the immune response and plays an indispensable role at the inflammation site by inducing pro-inflammatory cytokine production, finally resulting in CS. Short and slight periods of hypoxemia start even during the first manifestation of persistent cough and/or shortness of breath.
Conclusion: A more straightforward treatment strategy is to provide oxygen supply as early as possible, when the first respiratory symptoms begin, to prevent periods of hypoxemia outside the ICU. We have suggested using CPAP. Other methods such as Low or High-flow nasal oxygen HFNO therapy would provide the necessary oxygen at the lung alveoli to prevent gas exchange impairment, avoid hypoxemia, and therefore, avert CS.
Introduction
A specific adaptive immune response is initiated during early incubation and non-severe stages after SARS‐CoV-2 infection to exterminate the virus and halt disease progression. The second phase is characterized by the advent of systemic symptoms with unrestrained cytokine production, known as cytokine storm (CS) [1-3].
An exaggerated pro-inflammatory characterizes CS–mediated response and ineffective control by the anti-inflammatory system, leading to tissue damage, multiorgan failure, acute respiratory distress syndrome (ARDS), and death.[4-11].
Methods
We made a detailed review of the literature regarding the relationship between hypoxemia and CS in COVID-19 disease.
Results
Cytokine-mediated lung endothelial and epithelial cell injury may damage the integrity of the blood–air barrier, promoting vascular permeability, alveolar edema, infiltration, and the presence of inflammatory cells. As tissue breaks down, the walls of the lungs' tiny air sacs become leaky and fill with fluid starving the blood of oxygen, causing hypoxemia [12-16].
Hypoxemia triggers factors like HIF-1α, which regulates essential cellular processes, including cell proliferation, metabolism, and angiogenesis. HIF-1α is activated during the immune response and plays an indispensable role at the inflammation site by inducing pro-inflammatory cytokine production, finally resulting in CS [1-4], [17-20].
Discussion
COVID-19 presents mildly in most patients, commonly beginning during the first days of clinical evolution with fever followed by a dry cough and flu‐like symptoms. Nonetheless, short and slight periods of hypoxemia start even during the first manifestation of persistent cough and/or shortness of breath, as reported by authors using pulse oximetry and arterial gasometry.21 In some cases, during the second week of the clinical evolution, these symptoms may progress, leading to ARDS, closely related to the progressive increment of CS, which requires admission in intensive care units (ICU) with mechanical ventilation [1-3], [22-26]
Hence, the medical-scientific community is desperately trying to find treatments to avert CS. Several biologic interventions targeting inflammatory cytokines or related signaling pathways have been clinically evaluated with promising results, but without a final success to defeat this disease [27-36].
Hypoxemia is a decisive triggering factor for CS in COVID-19. CS generates additional hypoxia in tissues and organs, leading to a chain reaction between hypoxemia and CS [1, 2, 8, 9, 37, 38].
Conclusion
Therefore, a more straightforward treatment strategy is to provide oxygen supply as early as possible, when the first respiratory symptoms begin, to prevent periods of hypoxemia outside the intensive care units. Dr. Machado has suggested using CPAP.8 Other methods such as Low or High-flow nasal oxygen HFNO therapy, administered through nasal cannulae or a mask, would provide the necessary oxygen at the lung alveoli to prevent gas exchange impairment, avoid hypoxemia, and therefore, averting CS [3, 8].
Conflict of interest
Authors declare no conflicts of interest.
References
- Machado-Curbelo C. (2020) Silent or 'Happy' Hypoxemia: An Urgent Dilemma for COVID-19 Patient Care. MEDICC Rev; 22:85-6.
View at Publisher |
View at Google Scholar
- Machado-Curbelo C. (2020) Severe COVID-19 Cases: Is Respiratory Distress Partially Explained by Central Nervous System Involvement? MEDICC Rev; 22:38-9.
View at Publisher |
View at Google Scholar
- Machado C, González-Quevedo A. (2021) Hypoximia and cytokine storms in COVID-19: clinical implications. MEDICC Rev; 23:54–9.
View at Publisher |
View at Google Scholar
- Evans CE. (2019) Hypoxia and HIF activation as a possible link between sepsis and thrombosis. Thromb J; 17:16.
View at Publisher |
View at Google Scholar
- Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. (2021) Conceptions of the pathophysiology of happy hypoxemia in COVID-19. Respir Res; 22:12.
View at Publisher |
View at Google Scholar
- Anirvan P, Narain S, Hajizadeh N, Aloor FZ, Singh SP, Satapathy SK. (2019) Cytokine-induced liver injury in coronavirus disease- (COVID-19): untangling the knots. Eur J Gastroenterol Hepatol; 2021;Publish Ahead of Print.
View at Publisher |
View at Google Scholar
- Lupon E, Lellouch AG, Zal F, Cetrulo CL, Jr., Lantieri LA. (2021) Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO2Life(R) (M101). Med Hypotheses; 146:110421.
View at Publisher |
View at Google Scholar
- Machado C. (2021) Dangers and management of obstructive sleep apnea syndrome in COVID-19 patients. MEDICC Rev; 23.
View at Publisher |
View at Google Scholar
- Machado C, Gutierrez JV. (2020) Brainstem Dysfunction in SARS-COV2 Infection Can Be a Potential Cause of Respiratory Distress. Preprints; 2020040330.
View at Publisher |
View at Google Scholar
- Machado C, Mualem R, et al. (2020) It Is Imperative the use of Positive Air Pressure (CPAP) in Covid-19 Patients as Soon as the First Respiratory Symptoms Start. Frontiers Journal of Neurology and Neuroscience; 1:1-14.
View at Publisher |
View at Google Scholar
- Machado C, DeFina PA, Chinchilla M, Machado Y, Machado Y. (2020) Brainstem Dysfunction in SARS-COV-2 Infection can be a Potential Cause of Respiratory Distress. Neurol India; 68:989-93.
View at Publisher |
View at Google Scholar
- Wang X, Tu Y, Huang B, Li Y, Li Y, Zhang S, et al. (2020) Pulmonary vascular endothelial injury and acute pulmonary hypertension caused by COVID-19: the fundamental cause of refractory hypoxemia? Cardiovasc Diagn Ther; 10:892-7.
View at Publisher |
View at Google Scholar
- Saguil A, Fargo MV. (2020) Acute Respiratory Distress Syndrome: Diagnosis and Management. Am Fam Physician; 101:730-8.
View at Publisher |
View at Google Scholar
- Wang P, Luo R, Zhang M, Wang Y, Song T, Tao T, et al. (2020) A cross-talk between epithelium and endothelium mediates human alveolar-capillary injury during SARS-CoV-2 infection. Cell Death Dis; 11:1042.
View at Publisher |
View at Google Scholar
- Shao C, Liu H, Meng L, Sun L, Wang Y, Yue Z, et al. (2020) evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report. Hum Pathol; 101:82-8.
View at Publisher |
View at Google Scholar
- Nascimento Conde J, Schutt WR, Gorbunova EE, Mackow ER. (2020) Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. mBio; 11.
View at Publisher |
View at Google Scholar
- AbdelMassih A, Yacoub E, et al. (2021) Hypoxia-inducible factor (HIF): The link between obesity and COVID-19. Obes Med; 22:100317.
View at Publisher |
View at Google Scholar
- Taniguchi-Ponciano K, Majluf A, et al. (2021) Increased expression of hypoxia-induced factor 1alpha mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. Ann Med; 53:197-207.
View at Publisher |
View at Google Scholar
- Tian M, Liu W, Li X, Zhao P, Shereen MA, Zhu C, et al. (2021) HIF-1alpha promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Signal Transduct Target Ther; 6:308.
View at Publisher |
View at Google Scholar
- Yuan Y, Li Y, Qiao G, Zhou Y, Xu Z, Hill C, et al. (2021) Hyperbaric Oxygen Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice. Front Mol Biosci; 8:675437.
View at Publisher |
View at Google Scholar
- Parasher A. (2020) COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J;
View at Publisher |
View at Google Scholar
- Network C-IGobotR, the C-ICUI. (2021) Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med; 47:60-73.
View at Publisher |
View at Google Scholar
- Gonzalez-Martinez A, Fanjul V, Ramos C, Serrano Ballesteros J, Bustamante M, Villa Marti A, et al. (2021) Headache during SARS-CoV-2 infection as an early symptom associated with a more benign course of disease: a case-control study. Eur J Neurol;
View at Publisher |
View at Google Scholar
- Wang XH, Wang X, et al. (2021) High incidence and mortality of pneumothorax in critically Ill patients with COVID-19. Heart Lung; 50:37-43.
View at Publisher |
View at Google Scholar
- Leasa D, Group LVSfC-W. (2021) Knowledge translation tools to guide care of non-intubated patients with acute respiratory illness during the COVID-19 Pandemic. Crit Care25:22.
View at Publisher |
View at Google Scholar
- Bellani G, Grasselli G, Cecconi M, Antolini L, Borelli M, De Giacomi F, et al. Noninvasive Ventilatory Support of COVID-19 Patients Outside the Intensive Care Units (WARd-COVID). Ann Am Thorac Soc; 2021.
View at Publisher |
View at Google Scholar
- Ye Q, Wang B, Mao J. (2020) The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect; 80:607-13.
View at Publisher |
View at Google Scholar
- Verma YK, Verma R, Tyagi N, Behl A, Kumar S, Gangenahalli GU. (2020) COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. Stem Cell Rev Rep;
View at Publisher |
View at Google Scholar
- Rehman MFU, Fariha C, Anwar A, Shahzad N, Ahmad M, Mukhtar S, et al. Novel coronavirus disease (COVID-19) pandemic: A recent mini review. Comput Struct Biotechnol J; 2021;19:612-23.
View at Publisher |
View at Google Scholar
- Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, et al. (2021) Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol; 1-14.
View at Publisher |
View at Google Scholar
- Ong WY, Go ML, Wang DY, Cheah IK, Halliwell B. (2021) Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Mol Neurobiol; 58:106-17.
View at Publisher |
View at Google Scholar
- Li P, Lu Z, Li Q, Wang Z, Guo Y, Cai C, et al. (2021) Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6. Front Mol Biosci; 8:651662.
View at Publisher |
View at Google Scholar
- Stoy N. (2021) Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Front Immunol; 12:638446.
View at Publisher |
View at Google Scholar
- Moradinasab S, Pourbagheri-Sigaroodi A. (2021) Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities. Int Immunopharmacol; 97:107694.
View at Publisher |
View at Google Scholar
- Calabrese EJ, Kozumbo WJ, Kapoor R, Dhawan G, Jimenez PCL, Giordano J. (2021) NRF2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ards): novel mechanistic considerations. Radiother Oncol;
View at Publisher |
View at Google Scholar
- Ciampa ML, O'Hara TA, Joel CLet al. (2021) Absence of
View at Publisher |
View at Google Scholar
- Machado C,Cuspineda E, Machado Y. (2020) Continuous positive air pressure (CPAP) should be used in all COVID-19 patients when the first and mild respiratory symptoms commence. J Respir Dis Med 2:1-6.
View at Publisher |
View at Google Scholar
- Machado C.(2020) Early Prevention of Hypoxemia (Response to Peter S. Kim, Sarah W. Read, Anthony S. Fauci. Therapy for Early COVID-19: A Critical Need, published in JAMA. Published online. doi:10.1001/jama.2020.22813). JAMA;
View at Publisher |
View at Google Scholar